Previous results from our lab have shown that TLR2 stimulation of human regulatory T cells (Tregs), which have impaired suppressive function in MS patients (16, 17), leads to reduced Treg function and drives their differentiation toward an inflammatory Th17-like phenotype (18). The gene discussed is TLR2; the disease is myeloid sarcoma.